Charles Schwab’s Sagimet Biosciences SGMT Stock Holding History

Charles Schwab’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Buy	175,872 +160,872	+1,072%	+$1.09M	﹤0.01%	2911
2026 Q1	$78.4K	Hold	15,000	–	–	﹤0.01%	3402
2025 Q4	$88.8K	Hold	15,000	–	–	﹤0.01%	3403
2025 Q3	$103K	Hold	15,000	–	–	﹤0.01%	3392
2025 Q2	$114K	Hold	15,000	–	–	﹤0.01%	3410
2025 Q1	$48.9K	Buy	+15,000	New	+$62.9K	﹤0.01%	3402
2024 Q2	–	Sell	-51,869	Closed	-$281K	–	3675
2024 Q1	$281K	Buy	51,869 +39,307	+313%	+$282K	﹤0.01%	3188
2023 Q4	$68.1K	Hold	12,562	–	–	﹤0.01%	3373
2023 Q3	$111K	Buy	+12,562	New	+$167K	﹤0.01%	3343

Other funds holding SGMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Charles Schwab's SGMT Position: Q2 2026 in Review

Charles Schwab increased its Sagimet Biosciences (SGMT) stake by 1,072% in Q2 2026, buying an estimated $1.09M and bringing the position to 175,872 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Charles Schwab first reported a position in SGMT in Q3 2023 and has held it in 9 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

Charles Schwab held 175,872 shares of Sagimet Biosciences worth $1.36M as of Q2 2026.
Charles Schwab bought 160,872 Sagimet Biosciences shares in Q2 2026, an estimated $1.09M.
Sagimet Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2911 holding.
Charles Schwab first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 9 quarters since.
122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.